• Trendlyne logo
  • Markets
  • Alerts
  • F&O
  • MF
  • Reports
  • Screeners
  • Subscribe
  • Superstars
  • Portfolio
  • Watchlist
  • Insider Trades
  • Results
  • Data Downloader
  • Events Calendar
  • What's New
  • Explore
  • FAQs
  • Widgets
More
    Search stocks
    IND USA
    IND
    IND
    IND
    USA
    • Stocks
    • Futures & Options
    • Mutual Funds
    • News
    • Fundamentals
    • Reports
    • Corporate Actions
    • Alerts
    • Shareholding
    logo
    Blue Jet Healthcare Ltd
    10 Sep 2025
    679.45
    -0.56%
    Blue Jet Healthcare down 4% as promoter launches OFS at 675; check details
    Business Standard
    Blue Jet Healthcare's share price was trading 3.55 per cent lower at 704.8 per share compared to previous day's close of 730 on the NSE
    Copy LinkShare onShare on Share on Share on
    Blue Jet Healthcare Ltd has lost -20.63% in the last 3 Months
    logo
    Piramal Pharma Ltd.
    10 Sep 2025
    208.28
    2.43%
    Stock to buy today: Piramal Pharma(198.30)
    Business Line
    Traders can buy the stock now at 198 and accumulate at 195
    Copy LinkShare onShare on Share on Share on
    Piramal Pharma Ltd. is trading above its 150 day SMA of 204.9
    logo
    Sun Pharmaceutical Industries Ltd.
    09 Sep 2025
    1656.00
    0.45%
    Sun Pharma's Halol plant gets OAI classification from US FDA inspection
    Business Standard
    US FDA has classified Sun Pharma's Halol facility in Gujarat as OAI, keeping it under import alert, signalling possible enforcement action unless corrective steps are taken
    Copy LinkShare onShare on Share on Share on
    Sun Pharmaceutical Industries Ltd. is trading above its 50 day SMA of 1639.2
    Sun Pharma stock concerns may be overstated as domestic growth holds
    Business Standard | 09 Sep 2025
    logo
    Glenmark Pharmaceuticals Ltd.
    09 Sep 2025
    2085.20
    -1.10%
    Glenmark Pharma subsidiary IGI gets $700 million upfront payment from AbbVie
    Business Line
    The Mumbai-based drugmaker had in July announced this deal on itsdrug candidate that was in early Phase-I clinical trials and had shown promising outcomes in patients with relapsed / refractory multiple myeloma
    Copy LinkShare onShare on Share on Share on
    Geojit BNP Paribas increased Accumulate price target of Glenmark Pharmaceuticals Ltd. to 2306.0 on 09 Sep, 2025.
    Glenmark Pharma shares rise as arm receives an upfront payment of $700 mn
    Business Standard | 09 Sep 2025
    logo
    Morepen Laboratories Ltd.
    09 Sep 2025
    54.14
    0.28%
    Morepen Laboratories shares jump 6%; what's driving buying interest?
    Business Standard
    Morepen Laboratories shares jumped 5.7 per cent, after the company arm Morepen Medipath executed a joint venture (JV) agreement with Bimedical FZE, a UAE based entity
    Copy LinkShare onShare on Share on Share on
    Morepen Laboratories Ltd. is trading above its 50 day SMA of 54.1
    logo
    Amanta Healthcare Ltd.
    09 Sep 2025
    141.15
    1.46%
    Amanta Healthcare Shares To List Today: Here's What Latest GMP Signals Ahead Of Listing
    Amanta Healthcare Shares To List Today: Here's What Latest GMP Signals Ahead Of Listing
    NDTV Profit
    Ahead of its debut on the stock market, the shares of Amanta Healthcare are trading at a premium in the grey market, indicating positive gains for the investors.
    Copy LinkShare onShare on Share on Share on
    No SMAs available
    logo
    Strides Pharma Science Ltd.
    08 Sep 2025
    871.00
    -0.54%
    Strides enters into product partnership with Kenox for nasal spray
    Business Standard
    Strides Pharma Science Ltd on Monday said its Singapore-based subsidiary has entered into a strategic product development partnership with Kenox Pharmaceuticals Inc, which will strengthen the pipeline of nasal spray products across diverse therapeutic areas. Strides Pharma Global Pte, Singapore will collaborate with Kenox on the development and filing of multiple nasal spray products for the US market across diverse therapeutic indications, a joint statement said. The collaboration aims to accelerate affordable, high-quality medicines for patients in the US. However, it also mentioned that specific product details remain confidential at this stage. Kenox is a contract development and manufacturing company specialising in Orally Inhaled and Nasal Drug Products (OINDPs). Strides Pharma Science Executive Director Business Development Aditya Kumar said: "Weannounce this partnership with Kenox, a company that brings deep technical expertise in the OINDP space. Nasal sprays have...
    Copy LinkShare onShare on Share on Share on
    Strides Pharma Science Ltd. is trading above its 200 day SMA of 755.0
    Strides Pharma inks collaboration with Kenox for nasal spray portfolio in the US
    Business Line | 08 Sep 2025
    logo
    Mankind Pharma Ltd.
    08 Sep 2025
    2660.60
    0.85%
    Mankind Pharma gets CDSCO nod for Phase 1 trials for novel autoimmune drug
    Business Standard
    Mankind Pharma has received CDSCO approval to initiate Phase 1 trials of MKP11093, a novel JAK-1 inhibitor for autoimmune disorders, as part of its expanding R&D pipeline
    Copy LinkShare onShare on Share on Share on
    Mankind Pharma Ltd. is trading above all available SMAs
    CDSCO clears Mankind's Phase 1 trial for autoimmune disorder molecule
    Business Standard | 08 Sep 2025
    logo
    AstraZeneca Pharma India Ltd.
    07 Sep 2025
    8934.50
    -1.54%
    AstraZeneca's lung cancer combination boosted survival in key study
    Business Standard
    The combination helped patients with a specific type of advanced non-small cell lung cancer live for 47.5 months at the median, the longest survival benefit ever reported
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors increased from 164 to 181 in Jun 2025 qtr.
    logo
    AstraZeneca Pharma India Ltd.
    06 Sep 2025
    8934.50
    -1.54%
    AstraZeneca to invest 176 cr to expand GITC in Chennai
    Business Line
    The new investment, third in the past two years in India, will expand the GITC to strengthen its position as a leader in healthcare innovation both globally and in the country
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors increased from 164 to 181 in Jun 2025 qtr.
    Ashok Leyland to invest 7,500 cr in TN, AstraZeneca to expand GITC
    Business Standard | 06 Sep 2025
    more
    loading
    Trendlyne Logo Trendlyne
    Stay ahead of the market
    Markets Today
    • Nifty 50 today
    • Sensex today
    • Latest Quarterly results
    • FII & DII data today
    Dashboard
    • Industry & Sector analysis
    • ETFs
    • Mutual Funds
    • Bullish & Bearish spread
    • Global Indices
    Tools
    • Compare stocks
    • Widgets
    • Data Downloader
    • Excel Connect
    IPOs
    • Dashboard (Mainboard & SME)
    • Upcoming IPOs
    • Recently Listed IPOs
    • Most Successful IPOs
    Upcoming IPOs
    • JD Cables
    • GK Energy
    • Siddhi Cotspin
    Quick Links
    • Contact us
    • Blogs
    • FAQs
    Company
    • Privacy
    • Terms of Use
    • Disclaimer
    Trendlyne Products
    • Starfolio
    • SmartOptions
    • Trendlyne US Global
    Get Mobile App
    • Android
    • iOS

    Copyright © 2025 Giskard Datatech Pvt Ltd